NCT00207662View on ClinicalTrials.gov

A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

580

Participants

Timeline

Start Date

July 31, 2000

Study Completion Date

November 30, 2005

Conditions
Crohn Disease
Interventions
DRUG

infliximab or placebo

Sponsors

Lead Sponsor

Centocor, Inc.
All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY